Details

Autor(en) / Beteiligte

• Nghiem, Paul T
• Bhatia, Shailender
• Lipson, Evan J
• Kudchadkar, Ragini R
• Miller, Natalie J
• Annamalai, Lakshmanan
• Berry, Sneha
• Chartash, Elliot K
• Daud, Adil
• Fling, Steven P
• Friedlander, Philip A
• Kluger, Harriet M
• Kohrt, Holbrook E
• Lundgren, Lisa
• Margolin, Kim
• Mitchell, Alan
• Olencki, Thomas
• Pardoll, Drew M
• Reddy, Sunil A
• Shantha, Erica M
• Sharfman, William H
• Sharon, Elad
• Shemanski, Lynn R
• Shinohara, Michi M
• Sunshine, Joel C
• Taube, Janis M
• Thompson, John A
• Townson, Steven M
• Yearley, Jennifer H
• Topalian, Suzanne L
• Cheever, Martin A

Titel

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Ist Teil von

• The New England journal of medicine, 2016-06, Vol.374 (26), p.2542-2552

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Merkel-cell carcinoma is an aggressive neuroendocrine tumor that is poorly responsive to chemotherapy. In a small series of patients, pembrolizumab produced responses in a majority of patients, including some complete responses. The programmed death 1 (PD-1) immune checkpoint pathway, which comprises the PD-1 T-cell coinhibitory receptor and its ligands PD-L1 and PD-L2 expressed on tumor and immune cells in the tumor microenvironment, mediates local immune resistance. 1 Monoclonal antibodies blocking this pathway are active against advanced tumors of several different types, providing a “common denominator” for cancer therapy. 2 PD-L1 expression in pretreatment tumor specimens may identify patients and tumor types that are more likely to have a response to PD-1 pathway blockade, and PD-L1 immunohistochemical tests were recently approved by the Food and Drug Administration to guide clinical decision making for patients . . .